StreetInsider.com News Articles

BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

Fri, 28 Aug 2026 09:46:58 -0400

Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats.

The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine

BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

Fri, 28 Aug 2026 09:46:58 -0400

The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine

BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

Fri, 28 Aug 2026 09:46:58 -0400

The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine

BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

Fri, 28 Aug 2026 09:46:58 -0400

The timing of the setback could not be more vivid. Last week, Moderna and Merck reported a landmark Phase 3 success for their mRNA vaccine

BioNTech ends colorectal cancer mRNA therapy trial early

Fri, 28 Aug 2026 09:09:58 -0400

BioNTech SE (Nasdaq: BNTX) has terminated a Phase 2 clinical trial evaluating autogene cevumeran, an investigational individualized mRNA cancer immunotherapy, in patients with colorectal cancer (CRC), the company announced based on a recommendation from an independent oversight board.

The trial, designated BNT122-01, was assessing autogene cevumeran as an adjuvant monotherapy in patients with circulating tumor DNA-positive, surgically resected Stage II or Stage III CRC. The therapy is being jointly developed by BioNTech and Genentech, a member of the Roche Group.

The independent Data Safety Monitoring Board (DSMB) identified a numerical imbalance in overall survival between treatment arms and concluded that further continuation

BioNTech ends colorectal cancer mRNA therapy trial early

Fri, 28 Aug 2026 09:09:58 -0400

The independent Data Safety Monitoring Board (DSMB) identified a numerical imbalance in overall survival between treatment arms and concluded that further continuation

BioNTech ends colorectal cancer mRNA therapy trial early

Fri, 28 Aug 2026 09:09:58 -0400

The independent Data Safety Monitoring Board (DSMB) identified a numerical imbalance in overall survival between treatment arms and concluded that further continuation

BioNTech ends colorectal cancer mRNA therapy trial early

Fri, 28 Aug 2026 09:09:58 -0400

The independent Data Safety Monitoring Board (DSMB) identified a numerical imbalance in overall survival between treatment arms and concluded that further continuation

Form 6-K BioNTech SE For: Aug 28

Fri, 28 Aug 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260828/26993576.html

Form 6-K BioNTech SE For: Aug 28

Fri, 28 Aug 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260828/26993576.html

Form 6-K BioNTech SE For: Aug 28

Fri, 28 Aug 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260828/26993576.html

Form 6-K BioNTech SE For: Aug 27

Thu, 27 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260827/26990844.html

Form 6-K BioNTech SE For: Aug 27

Thu, 27 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260827/26990844.html

Form 6-K BioNTech SE For: Aug 27

Thu, 27 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260827/26990844.html

FDA approves Pfizer-BioNTech XFG-targeted Covid-19 vaccine

Thu, 27 Aug 2026 16:30:18 -0400

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on August 27, 2026, that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine targeting the XFG variant, sold under the brand name Comirnaty.

The approved vaccine is indicated for adults aged 65 and older, as well as individuals aged 5 through 64 who have at least one underlying condition placing them at high risk for severe COVID-19 outcomes.